Download PDF
Exp Clin Endocrinol Diabetes 1996; 104(2): 177-179
DOI: 10.1055/s-0029-1211441
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Lack of islet amyloid polypeptide/amylin-immunoreactivity in urine collected from healthy volunteers after ingestion of a carbohydrate-rich meal

K. L. van Hulst1 , 2 , M. G. Nieuwenhuis1 , J. W. M. Höppener1 , 3 , C. J. M. Lips1 , M. A. Blankenstein2
  • 1Department of Internal Medicine, Utrecht University, Utrecht, The Netherlands
  • 2Department of Endocrinology, Utrecht University, Utrecht, The Netherlands
  • 3Department of Pathology, Utrecht University, Utrecht, The Netherlands
Further Information

Publication History

Publication Date:
15 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Islet amyloid polypeptide (IAPP), or amylin, is synthesized by β cells in the islets of Langerhans of the pancreas. Plasma IAPP levels are highly elevated in patients with advanced renal failure. To investigate the involvement of the kidney in the clearance of IAPP, the response of plasma and urinary IAPP to a carbohydrate-rich meal was investigated in 14 healthy volunteers. Although plasma IAPP levels increased severalfold after the meal, no IAPP-immunoreactivity was detected in the urine samples up to 4 hours after the meal. This might be due to the fact that urinary IAPP levels are under the detection limit of the assay or, assuming the presence of IAPP in the primary urine, immunoreactive IAPP molecules may be processed by renal mechanisms in such a way that they are no longer recognized by the antibodies used in the radioimmunoassay. Processed IAPP molecules may be reabsorbed in the proximal tubules of the kidney and/or excreted.

Key words

islet amyloid polypeptide - IAPP - amylin - urine - ß-cell stimulation

      >